ICD-10-CM Billable Code

D29.1

Benign neoplasm of prostate

Clinical Classification Guidelines

Excludes Type 1

  • enlarged prostate (N40.-)

Medical Intelligence & Overview

Benign neoplasm of the prostate, classified under ICD-10 code D29.1, refers to a non-cancerous growth that develops in the prostate gland. Often called benign prostatic hyperplasia (BPH) or benign prostatic tumor, this condition involves an increase in the number of cells within the prostate, leading to enlargement of the gland. While not malignant, its growth can influence urinary function and overall prostate health, particularly in older men. Understanding this condition is essential for recognizing symptoms and exploring treatment options to manage its effects.

Causes & Symptoms

Clinical Causes: Age-related hormonal changes Increase in dihydrotestosterone (DHT) levels Genetic predisposition Family history of prostate conditions Inflammation or infections of the prostate Lifestyle factors such as obesity and lack of physical activity

Key Symptoms: Frequent need to urinate, especially at night Weak or interrupted urinary stream Difficulty starting urination Feeling of incomplete bladder emptying Urgency to urinate Acute urinary retention in severe cases Discomfort or pain during urination or ejaculation Blood in urine, though less common

Diagnostic & Treatment

Diagnosis Path: Diagnosis of a benign neoplasm of the prostate typically involves a combination of medical history, physical examination, and diagnostic tests. The following are common diagnostic steps: - Digital Rectal Examination (DRE): The healthcare provider assesses the size and texture of the prostate. - Prostate-Specific Antigen (PSA) Test: Measures PSA levels in the blood, which may be elevated in BPH. - Urinalysis: Checks for infections or other urinary issues. - Imaging Tests: Ultrasound or MRI scans to visualize the prostate. - Urodynamic Studies: Assess the flow of urine and bladder function. - Biopsy: In certain cases, tissue samples may be taken to rule out cancer, especially if PSA levels are suspicious. Early diagnosis helps differentiate benign conditions from prostate cancer and other urinary problems.

Treatment Protocols: Management of a benign neoplasm of the prostate varies depending on the severity of symptoms and overall health. Common treatment options include: - Watchful Waiting: Monitoring without active treatment, suitable for mild symptoms. - Medications: - Alpha-blockers (e.g., tamsulosin): Relax prostate muscles to improve urine flow. - 5-alpha-reductase inhibitors (e.g., finasteride): Shrink prostate size by affecting hormone levels. - Minimally Invasive Procedures: - Transurethral resection of the prostate (TURP): Removal of excess prostate tissue using a scope. - Laser therapy: Uses laser energy to reduce prostate size. - Surgical Options: In severe cases, prostatectomy may be performed to remove enlarged tissue. - Lifestyle Modifications: Including fluid management, pelvic exercises, and avoiding irritants such as caffeine and alcohol. Patients are advised to consult healthcare providers for personalized management plans tailored to their specific condition and health status.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is D29.1 a billable ICD-10 code?
Yes, D29.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report D29.1?
Clinical documentation must specify the nature of Benign neoplasm of prostate and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

neoplasm prostate